Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Biocon Biologics Limited
483
•Biocon Biologics Limited•May 1, 2018

Biocon Biologics Limited – FDA 483, May 1, 2018

Record Details

The FDA Form 483 details several deficiencies at the facility. Disinfection efficacy studies for the Filling and Finish Area (BF/STY/001/P) did not demonstrate adequate control of microbial contamination or confirm residual disinfectant levels. A separate study (BF/CQC8/STY/P/313) used a spray application method for disinfectants on coupons, which differs from the mop and wipe application used in production areas, potentially impacting real-world efficacy.

Environmental monitoring is deficient, specifically lacking microbial monitoring for open operations during drug product formulation, preparation, compounding, and in LAF-026 (Grade C).

Cleaning procedures are inadequate. During manual glassware cleaning in the Grade D washroom F072, product contact surfaces were not fully exposed to cleaning agents, glassware was not filled as per SOP BF/FM/SOP/019 version 4, and glassware lids were not included in the cleaning procedure.

Inadequate behaviors to prevent raw material contamination were observed during dispensing. An operator cleaned the floor without changing or sanitizing gloves before resuming dispensing. Raw material containers were not sanitized before entering the dispensing hood. The same wipe was used to clean the balance and surrounding table. Raw material was stored in a battered cardboard box, and its transfer into a bin before entering the dispensing booth was noted, despite the material specification including endotoxin limits.

Operating procedures for dispensing were inconsistent. SOP CQC/M/SOP/

Company
Biocon Biologics Limited
Inspection date
May 1, 2018
Office
Office of Pharmaceutical Manufacturing Assessment
People
  • Laura Fontan (investigator)
  • Laurie A. Nelson
View Company Profile

ID · 6fa7e974-b5c4-450b-bb8f-8eb76ae4b514

Violation Codes2
21 CFR 21021 CFR 211

Full citation text and observation details available on the Dashboard.

Other documents for Biocon Biologics Limited
  • 483 - 2026-04-29April 29, 2026
  • 483 - 2024-07-26July 26, 2024
  • 483 - 2022-08-26August 26, 2022
  • 483 - 2022-08-19August 19, 2022
  • 483 - 2019-09-19September 19, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Biocon Biologics Limited
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.